

# Anthony D'Amico

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7933170/publications.pdf>

Version: 2024-02-01

44  
papers

2,083  
citations

304743

22  
h-index

302126

39  
g-index

45  
all docs

45  
docs citations

45  
times ranked

2864  
citing authors

#	ARTICLE	IF	CITATIONS
1	MRI-Based Radiotherapy Planning to Reduce Rectal Dose in Excess of Tolerance. <i>Prostate Cancer</i> , 2022, 2022, 1-9.	0.6	3
2	The Influence of Phototherapy on Recovery From Exercise-Induced Muscle Damage. <i>International Journal of Sports Physical Therapy</i> , 2022, 17, .	1.3	1
3	Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy. <i>Prostate</i> , 2022, 82, 1098-1106.	2.3	2
4	Clinicopathological and molecular characteristics of prostate cancer diagnosed in young men aged up to 45 years. <i>Histopathology</i> , 2021, 78, 857-870.	2.9	1
5	Radiation Delay Is Okay, but Where Is the Evidence?â€”Reply. <i>JAMA Oncology</i> , 2021, 7, 464.	7.1	0
6	Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 150-169.	5.4	23
7	Prostate-specific antigen levels of $\leq 4$ and $> 4$ ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer. <i>Cancer</i> , 2021, 127, 2222-2228.	4.1	6
8	Reply to Benefit-harm ratio of the diagnostic workup in patients with prostate cancer of Gleason score from 9 to 10. <i>Cancer</i> , 2021, 127, 4312-4312.	4.1	0
9	Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. <i>Cancer</i> , 2020, 126, 717-724.	4.1	64
10	Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2020, 6, 1630.	7.1	25
11	Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2020, 38, 3032-3041.	1.6	37
12	Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 2379-2389.	2.8	24
13	Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. <i>Cancer</i> , 2019, 125, 3338-3346.	4.1	15
14	Cancer Screening Patterns Among Current, Former, and Never Smokers in the United States, 2010-2015. <i>JAMA Network Open</i> , 2019, 2, e193759.	5.9	34
15	Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 704.	7.4	168
16	Reply to Partial gland therapy for prostate cancer. <i>Cancer</i> , 2019, 125, 819-820.	4.1	0
17	Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 652.	7.1	41
18	Decipher Postprostatectomy: Is It Ready for Clinical Use?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1976-1977.	1.6	5

#	ARTICLE	IF	CITATIONS
19	Reply to D.E. Spratt. Journal of Clinical Oncology, 2017, 35, 2979-2979.	1.6	0
20	Gleason score and the risk of cause-specific and all-cause mortality following radiation with or without 6 months of androgen deprivation therapy for men with unfavorable-risk prostate cancer. Journal of Radiation Oncology, 2016, 5, 301-308.	0.7	0
21	Pelvis Plus Prostate Radiation Therapy and the Risk of Death in Men With Newly Diagnosed Node-Positive Prostate Cancer. JAMA Oncology, 2016, 2, 357.	7.1	1
22	Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer—Reply. JAMA - Journal of the American Medical Association, 2016, 315, 1055.	7.4	3
23	Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of Death. European Urology, 2016, 69, 976-979.	1.9	51
24	A Systematic Review of Hypofractionation for Primary Management of Prostate Cancer. European Urology, 2015, 68, 683-691.	1.9	90
25	Risk Group and Death From Prostate Cancer. JAMA Oncology, 2015, 1, 334.	7.1	60
26	Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. European Urology, 2015, 68, 756-765.	1.9	57
27	Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2015, 314, 1291.	7.4	121
28	Percent positive biopsy cores and the risk of death from prostate cancer in men with unfavorable-risk prostate cancer. Journal of Radiation Oncology, 2014, 3, 307-312.	0.7	0
29	Natural History of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer in Men with Favorable Prognostic Indicators. Prostate Cancer, 2014, 2014, 1-6.	0.6	5
30	Personalizing the Management of Men with Intermediate-risk Prostate Cancer. European Urology, 2013, 64, 903-904.	1.9	10
31	Population-based determinants of radical prostatectomy surgical margin positivity. BJU International, 2011, 107, 1734-1740.	2.5	22
32	Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU International, 2010, 106, 627-632.	2.5	38
33	Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. BJU International, 2010, 106, 979-985.	2.5	22
34	The "CaP Calculator"™: an online decision support tool for clinically localized prostate cancer. BJU International, 2010, 105, 1417-1422.	2.5	19
35	Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective ? identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy. BJU International, 2007, 99, 13-16.	2.5	8
36	USING PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME IN CLINICAL PRACTICE. BJU International, 2007, 100, 243-244.	2.5	7

#	ARTICLE	IF	CITATIONS
37	Prostate Cancer Prevention and Finasteride. Journal of Urology, 2006, 176, 2010-2013.	0.4	18
38	Predictors of Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation Therapy. Journal of Clinical Oncology, 2005, 23, 6992-6998.	1.6	185
39	Cancer-Specific Mortality After Surgery or Radiation for Patients With Clinically Localized Prostate Cancer Managed During the Prostate-Specific Antigen Era. Journal of Clinical Oncology, 2003, 21, 2163-2172.	1.6	425
40	Time Course and Predictors of Symptoms After Primary Prostate Cancer Therapy. Journal of Clinical Oncology, 2003, 21, 3979-3986.	1.6	196
41	Lower Prostate Specific Antigen Outcome Than Expected Following Radical Prostatectomy in Patients With High Grade Prostate and a Prostatic Specific Antigen Level of 4 Ng/ML. or Less. Journal of Urology, 2002, 167, 2025-2031.	0.4	39
42	Predicting Prostate-Specific Antigen Recurrence Established: Now, Who Will Survive?. Journal of Clinical Oncology, 2002, 20, 3188-3190.	1.6	11
43	Evaluation of three-dimensional finite element-based deformable registration of pre- and intraoperative prostate imaging. Medical Physics, 2001, 28, 2551-2560.	3.0	201
44	Utilizing Predictions of Early Prostate-Specific Antigen Failure to Optimize Patient Selection for Adjuvant Systemic Therapy Trials. Journal of Clinical Oncology, 2000, 18, 3240-3246.	1.6	44